Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BellRing Brands, Inc. for alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation - The law firm is looking into claims against BellRing Brands, Inc. related to misleading statements about the company's sales growth and competition impact [4]. - Investors who purchased BellRing securities between November 19, 2024, and August 4, 2025, and suffered losses exceeding $50,000 are encouraged to contact the firm [1][2]. Group 2: Class Action Details - A federal securities class action has been filed against BellRing, with a deadline of March 23, 2026, for investors to seek the role of lead plaintiff [2][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Firefly Aerospace Inc. is facing a federal securities class action due to allegations of misleading statements regarding its business operations and financial performance, with a deadline for investors to seek lead plaintiff status set for January 12, 2026 [1][3]. Group 1: Allegations and Financial Performance - The complaint alleges that Firefly and its executives violated federal securities laws by making false statements about the demand and growth prospects for its Spacecraft Solutions offerings [3]. - Firefly's operational readiness and commercial viability of its Alpha rocket program were also overstated, which could have a material negative impact on the company once revealed [3]. - In its first earnings report as a public company, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, for the same quarter in 2024 [5]. - Revenue for the second quarter of 2025 was reported at $15.55 million, below analyst estimates of $17.25 million and down 26.2% from the same quarter in 2024 [5]. - The Spacecraft Solutions business segment generated only $9.2 million in revenue, representing a 49% year-over-year decrease [5]. Group 2: Stock Price Impact - Following the earnings report, Firefly's stock price fell by $7.58 per share, or 15.31%, closing at $41.94 per share on September 23, 2025 [6]. - After the disclosure of a failure in the Alpha Flight 7 rocket, the stock price dropped by $7.66 per share, or 20.73%, closing at $29.30 per share on September 30, 2025 [8]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and will oversee the litigation [9]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [9]. - The law firm Faruqi & Faruqi encourages individuals with information regarding Firefly's conduct to come forward, including whistleblowers and former employees [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch of its Inspire V device, which has led to significant financial losses for investors [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Inspire Medical to contact them to discuss legal options, particularly in light of a federal securities class action with a deadline of January 5, 2026, for seeking the role of lead plaintiff [1][2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Inspire Medical - The complaint alleges that Inspire Medical and its executives violated federal securities laws by making false and misleading statements about the market demand for the Inspire V device and the company's readiness for its launch [4]. - On August 4, 2025, Inspire Medical announced significant setbacks in the launch of the Inspire V device, citing delays due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges [5]. Group 3: Financial Impact - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a drastic cut in its 2025 earnings guidance by over 80% [6]. - Following the announcement of these issues, Inspire's stock price plummeted by more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Firefly Aerospace Inc. due to allegations of misleading statements and operational issues that have negatively impacted the company's stock performance and investor confidence [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Firefly Aerospace to discuss their legal options, particularly those who purchased shares during the IPO or within the defined class period [1][2]. - A federal securities class action has been filed against Firefly, with a deadline of January 12, 2026, for investors to seek the role of lead plaintiff [2]. Group 2: Financial Performance and Stock Impact - Firefly conducted its IPO on August 7, 2025, selling 19.296 million shares at $45.00 per share [5]. - In its first earnings report as a public company, Firefly reported a loss of $80.3 million, or $5.78 per share, which was an increase from a loss of $58.7 million, or $4.60 per share, in the same quarter of 2024 [6]. - Revenue for the second quarter of 2025 was reported at $15.55 million, falling short of analyst estimates of $17.25 million and down 26.2% year-over-year [6]. - The Spacecraft Solutions business segment saw a significant revenue decline of 49% year-over-year, with only $9.2 million reported [6]. - Following the earnings report, Firefly's stock price dropped by $7.58, or 15.31%, closing at $41.94 per share [7]. - After a subsequent announcement regarding a failure in the Alpha Flight 7 rocket, the stock price fell further by $7.66, or 20.73%, closing at $29.30 per share [9]. Group 3: Allegations of Misleading Statements - The complaint against Firefly alleges that the company overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program [4]. - It is claimed that these misrepresentations would likely have a material negative impact on the company once revealed, affecting the integrity of the Offering Documents and public statements made during the class period [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to alleged violations of federal securities laws related to misleading statements about the launch of the Inspire V device and its market demand [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. - Investors who suffered losses in Inspire Medical are encouraged to contact the firm to discuss their legal options [1]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays due to incomplete training and onboarding at treatment centers [5]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, affecting the ability to bill for procedures [5]. - Inspire reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Market Impact - Following the announcement of these issues, Inspire Medical's stock price dropped over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Petco Health and Wellness Company, Inc. due to allegations of misleading statements and failure to disclose critical business issues, with a deadline for investors to seek lead plaintiff status in a federal securities class action by August 29, 2025 [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Petco between January 14, 2021, and June 5, 2025, to discuss their legal rights [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Petco - The complaint alleges that Petco's pandemic-related business advantages were unsustainable and that its business model focused on premium pet food was overstated [4]. - It is claimed that the executives downplayed the severity of issues affecting the company and overstated its ability to achieve sustainable growth [4]. Group 3: Financial Performance - On June 5, 2025, Petco reported first-quarter net sales of $1.5 billion, reflecting a 2.3% year-over-year decline [5]. - Following the financial results announcement, Petco's stock price dropped by $0.85 per share, or 23.34%, closing at $2.78 per share on June 6, 2025 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth prospects and business performance [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Vestis between May 2, 2024, and May 6, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vestis, with a deadline of August 8, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Vestis - The complaint alleges that Vestis and its executives disseminated materially false and misleading statements regarding the company's ability to grow its business [4]. - Vestis announced poor financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year, attributing the decline to "lost business in excess of new business" and "lower adds over stops" [5]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [5]. Group 3: Investor Communication - Faruqi & Faruqi, LLP is encouraging anyone with information regarding Vestis' conduct, including whistleblowers and former employees, to contact the firm [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the May 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Geron [2]. - The complaint alleges that Geron and its executives made false and misleading statements regarding the company's drug Rytelo, downplaying risks associated with its monitoring requirements and competition [4]. - Investors who suffered losses exceeding $100,000 in Geron between February 28, 2024, and February 25, 2025, are encouraged to contact the firm for legal options [1]. Group 2: Financial Performance and Stock Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had flattened due to seasonality, competition, and lack of awareness [5]. - Following the announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [6].